Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stauch

Showing results (151-160 of 161) with videos related to

Pageof 17
Sort By:
Oncology|June 3, 2008
Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancerD Laessig, H J Stemmler, U Vehling-Kaiser, et al.
Oncology|April 6, 2005
High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancerJ Stemmler, W Mair, M Stauch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 27, 2007
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancerS Boeck, T Hoehler, G Seipelt, et al.
Leukemia|October 19, 2011
Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicityC Kellner, D Hallack, P Glorius, et al.
Leukemia|June 5, 2012
The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cellsP Glorius, A Baerenwaldt, C Kellner, et al.
International Journal of Cancer|August 19, 2015
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial)A Stahler, V Heinemann, C Giessen-Jung, et al.
Leukemia|May 16, 2012
Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemiaT Elter, R James, R Busch, et al.
British Journal of Cancer|July 14, 2011
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trialS Stintzing, L Fischer von Weikersthal, U Vehling-Kaiser, et al.
Journal of Cancer Research and Clinical Oncology|May 13, 2014
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trialJ C von Einem, V Heinemann, L Fischer von Weikersthal, et al.
European Journal of Cancer (Oxford, England : 1990)|May 3, 2017
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) studyS Stintzing, L Miller-Phillips, D P Modest, et al.
Pageof 17

Showing results (151-160 of 161) with videos related to

Sort By:
Pageof 17
Oncology|June 3, 2008
Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancerD Laessig, H J Stemmler, U Vehling-Kaiser, et al.
Oncology|April 6, 2005
High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancerJ Stemmler, W Mair, M Stauch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 27, 2007
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancerS Boeck, T Hoehler, G Seipelt, et al.
Leukemia|October 19, 2011
Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicityC Kellner, D Hallack, P Glorius, et al.
Leukemia|June 5, 2012
The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cellsP Glorius, A Baerenwaldt, C Kellner, et al.
International Journal of Cancer|August 19, 2015
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial)A Stahler, V Heinemann, C Giessen-Jung, et al.
Leukemia|May 16, 2012
Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemiaT Elter, R James, R Busch, et al.
British Journal of Cancer|July 14, 2011
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trialS Stintzing, L Fischer von Weikersthal, U Vehling-Kaiser, et al.
Journal of Cancer Research and Clinical Oncology|May 13, 2014
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trialJ C von Einem, V Heinemann, L Fischer von Weikersthal, et al.
European Journal of Cancer (Oxford, England : 1990)|May 3, 2017
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) studyS Stintzing, L Miller-Phillips, D P Modest, et al.
Pageof 17